🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for Primary Autoimmune Hemolytic Anemia

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders NCT07104565Phase 239 sites📍 Glendale📍 Los Angeles📍 Lone Tree Incyte Corporation · Tests: INCA000585 Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC NCT04528355n/a1 site📍 Pittsburgh Paul Szabolcs · Tests: data collection Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study NCT05089227Phase 21 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: treatment "intervention", treatment "standard", biological assessment Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases NCT07441525EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: CART Infusion Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 Second-line Treatment of Primary Autoimmune Hemolytic Anemia NCT05057468Phase 32 sites📍 Asyut📍 Asyut Assiut University · Tests: Cyclosporine, Rituximab Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy